# Low-Intensity Extracorporeal Shock Wave Therapy Alleviates Detrusor Muscle Apoptosis and Extracellular Matrix Dysregulation in the Bladder of Diabetic Rats

**Authors:** Yau-Hsuan Tsau, Hsun-Shuan Wang, I-Hsuan Tsai, Miao-Yi Wu, Chia-Chu Liu, Tusty-Jiuan Hsieh, Yung-Chin Lee

PMC · DOI: 10.7150/ijms.121078 · 2026-02-18

## TL;DR

Low-intensity shock wave therapy helps reverse bladder damage in diabetic rats by reducing muscle cell death and fibrosis.

## Contribution

This study reveals the molecular mechanisms by which Li-ESWT improves diabetic bladder dysfunction in rats.

## Key findings

- Li-ESWT reduces muscle atrophy, apoptosis, and fibrosis in diabetic rat bladders.
- Li-ESWT restores α-smooth muscle actin expression and lowers cleaved caspase-3, TGF-β1, and collagen I levels.
- Li-ESWT shows potential to reverse structural and functional bladder abnormalities in diabetes.

## Abstract

Diabetic bladder dysfunction (DBD) affects 80% of diabetic patients, especially women. Yet, the management of DBD remains inconclusive. Building on our previous findings in animal models, low-intensity extracorporeal shock wave therapy (Li-ESWT) seems to be a promising potential therapy for DBD. However, the molecular mechanisms underlying the therapeutic effect of Li-ESWT on DBD still need to be clarified. To elucidate the molecular pathways involved in the therapeutic effect of Li-ESWT on DBD, a diabetic rat model was established using a high-fat diet in combination with streptozotocin (STZ) induction. Female Sprague-Dawley rats were randomly assigned to three groups: control, diabetes mellitus (DM), and DM treated with Li-ESWT for four weeks. To induce diabetes, the rats received a high-fat diet followed by two intraperitoneal injections of STZ (30 mg/kg), administered one week apart. Li-ESWT was delivered once weekly for four weeks, using an energy flux density of 0.03 mJ/mm², 500 shocks per session, at a frequency of 3 Hz. Our findings indicate that Li-ESWT significantly ameliorates pathological bladder changes, including muscle atrophy, apoptosis, and fibrosis, in diabetic rats. The expression of α-smooth muscle actin, a key component of the smooth muscle cytoskeleton, was markedly reduced in diabetic bladders but was partially restored following Li-ESWT treatment. Additionally, elevated levels of cleaved caspase-3, transforming growth factor-β1, and collagen I observed in diabetic bladders were attenuated by Li-ESWT. In summary, Li-ESWT exerts restorative effects on the detrusor smooth muscle, suggesting its potential to reverse structural and functional abnormalities in diabetic bladder dysfunction.

## Linked entities

- **Chemicals:** streptozotocin (PubChem CID 29327)
- **Diseases:** diabetes mellitus (MONDO:0005015)

## Full-text entities

- **Genes:** Fbxo32 (F-box protein 32) [NCBI Gene 171043] {aka Atrogin1, MAFbx}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 24383] {aka BARS-38, Gapd}, Bak1 (BCL2-antagonist/killer 1) [NCBI Gene 116502] {aka Bak}, Dntt (DNA nucleotidylexotransferase) [NCBI Gene 294051], Bax (BCL2 associated X, apoptosis regulator) [NCBI Gene 24887], Actg2 (actin gamma 2, smooth muscle) [NCBI Gene 25365] {aka ACTGE, SMGA}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 59086] {aka Tgfb}, ADRB3 (adrenoceptor beta 3) [NCBI Gene 155] {aka BETA3AR}, Myocd (myocardin) [NCBI Gene 246297] {aka Mycd}, Myh2 (myosin heavy chain 2) [NCBI Gene 691644] {aka MyHC-2A, MyHC-IIA, Myh1, Myh2a}, Bcl2l1 (Bcl2-like 1) [NCBI Gene 24888] {aka Bcl-xl, Bcl2l, Bclx, bcl-X}, Bcl2 (BCL2, apoptosis regulator) [NCBI Gene 24224] {aka Bcl-2}, Casp3 (caspase 3) [NCBI Gene 25402] {aka CPP32-beta, Lice, Yama}, Nos1 (nitric oxide synthase 1) [NCBI Gene 24598] {aka bNOS}
- **Diseases:** OAB (MESH:D053201), DM (MESH:D003920), atrophy (MESH:D001284), inflammation (MESH:D007249), muscle atrophy (MESH:D009133), Metabolic disturbances (MESH:D024821), hyperglycemia (MESH:D006943), fibrosis (MESH:D005355), metabolic disorder (MESH:D008659), neurologic dysfunction (MESH:D009461), DBD (MESH:D001745), lithiasis (MESH:D020347), infections (MESH:D007239), urothelial dysfunction (MESH:D014522), erectile dysfunction (MESH:D007172), Long-term diabetes (MESH:D000088562), microvascular damage (MESH:D017566), pelvic pain (MESH:D017699), urinary incontinence (MESH:D014549), penile curvature (MESH:D013121), detrusor underactivity (MESH:D000077295), LUTD (MESH:D014570), detrusor smooth muscle dysfunction (MESH:D018235), prostatitis (MESH:D011472), neuronal damage (MESH:D009410), type 2 diabetes (MESH:D003924), renal damage (MESH:D007674)
- **Chemicals:** BrdU (MESH:D001973), polyacrylamide (MESH:C016679), fat (MESH:D005223), oxygen (MESH:D010100), 4-HNE (MESH:C027576), SDS (MESH:D012967), NO (MESH:D009569), aldehydes (MESH:D000447), blood glucose (MESH:D001786), Isoflurane (MESH:D007530), Li (MESH:D008094), STZ (MESH:D013311), dUTP (MESH:C027078), MDA (MESH:D008315), carbohydrate (MESH:D002241), CF  488A (-), H&amp;E (MESH:D006371), Hematoxylin (MESH:D006416), Eosin (MESH:D004801), DAB (MESH:C000469), PVDF (MESH:C024865), DAPI (MESH:C007293), glucose (MESH:D005947), formalin (MESH:D005557), ROS (MESH:D017382), lipid (MESH:D008055)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986]
- **Cell lines:** Sc377460 — Homo sapiens (Human), Follicular lymphoma, Cancer cell line (CVCL_1888)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12965066/full.md

---
Source: https://tomesphere.com/paper/PMC12965066